| pubmed-article:8864439 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8864439 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8864439 | lifeskim:mentions | umls-concept:C0194037 | lld:lifeskim |
| pubmed-article:8864439 | lifeskim:mentions | umls-concept:C0024305 | lld:lifeskim |
| pubmed-article:8864439 | lifeskim:mentions | umls-concept:C1517677 | lld:lifeskim |
| pubmed-article:8864439 | lifeskim:mentions | umls-concept:C1548399 | lld:lifeskim |
| pubmed-article:8864439 | lifeskim:mentions | umls-concept:C0163054 | lld:lifeskim |
| pubmed-article:8864439 | lifeskim:mentions | umls-concept:C0332167 | lld:lifeskim |
| pubmed-article:8864439 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:8864439 | pubmed:dateCreated | 1997-1-3 | lld:pubmed |
| pubmed-article:8864439 | pubmed:abstractText | Between June 1990 and January 1994, 19 patients with non-Hodgkin's lymphoma (NHL) at high risk for bone marrow involvement underwent 4-hydroperoxycyclophosphamide (4-HC) purged bone marrow transplantation. Eleven patients had low grade, seven intermediate grade and one high grade NHL and 7/19 patients had received three or more previous chemotherapeutic regimens. Four patients were transplanted in first partial remission (PR) and the remainder in responsive relapse. Fourteen patients had bone marrow (BM) involvement at diagnosis and/or at relapse. The median times to granulocyte and platelet recovery were 26 and 29 days, respectively. There were two toxic deaths and one complete responder developed secondary AML at 31 months post-BMT. Seventeen of 18 evaluable patients achieved a complete remission (CR) and one patient a PR. Fourteen patients (74%) are progression-free at a median follow-up of survivors of 34 months (range 29-55). The 3 year event-free (EFS) and overall survival (OS) probabilities are both 67%. No statistically significant difference was seen between EFS or OS and BM involvement or histologic grade at diagnosis. At 29 months, 4/7 patients with a morphologically involved BM harvest had relapsed or died compared to 1/12 patients with negative BM (P = 0.03). These results are encouraging and warrant further investigation of 4-HC purging in NHL. | lld:pubmed |
| pubmed-article:8864439 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8864439 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8864439 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8864439 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8864439 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8864439 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8864439 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8864439 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:8864439 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:8864439 | pubmed:author | pubmed-author:BallJJ | lld:pubmed |
| pubmed-article:8864439 | pubmed:author | pubmed-author:SchultzD JDJ | lld:pubmed |
| pubmed-article:8864439 | pubmed:author | pubmed-author:LugerSS | lld:pubmed |
| pubmed-article:8864439 | pubmed:author | pubmed-author:SilbersteinLL | lld:pubmed |
| pubmed-article:8864439 | pubmed:author | pubmed-author:BirdJ MJM | lld:pubmed |
| pubmed-article:8864439 | pubmed:author | pubmed-author:EdelsteinMM | lld:pubmed |
| pubmed-article:8864439 | pubmed:author | pubmed-author:StadtmauerE... | lld:pubmed |
| pubmed-article:8864439 | pubmed:author | pubmed-author:ManganPP | lld:pubmed |
| pubmed-article:8864439 | pubmed:author | pubmed-author:PowlisWW | lld:pubmed |
| pubmed-article:8864439 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8864439 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:8864439 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8864439 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8864439 | pubmed:pagination | 309-13 | lld:pubmed |
| pubmed-article:8864439 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8864439 | pubmed:meshHeading | pubmed-meshheading:8864439-... | lld:pubmed |
| pubmed-article:8864439 | pubmed:meshHeading | pubmed-meshheading:8864439-... | lld:pubmed |
| pubmed-article:8864439 | pubmed:meshHeading | pubmed-meshheading:8864439-... | lld:pubmed |
| pubmed-article:8864439 | pubmed:meshHeading | pubmed-meshheading:8864439-... | lld:pubmed |
| pubmed-article:8864439 | pubmed:meshHeading | pubmed-meshheading:8864439-... | lld:pubmed |
| pubmed-article:8864439 | pubmed:meshHeading | pubmed-meshheading:8864439-... | lld:pubmed |
| pubmed-article:8864439 | pubmed:meshHeading | pubmed-meshheading:8864439-... | lld:pubmed |
| pubmed-article:8864439 | pubmed:meshHeading | pubmed-meshheading:8864439-... | lld:pubmed |
| pubmed-article:8864439 | pubmed:meshHeading | pubmed-meshheading:8864439-... | lld:pubmed |
| pubmed-article:8864439 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8864439 | pubmed:articleTitle | 4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation in non-Hodgkin's lymphoma patients at high risk of bone marrow involvement. | lld:pubmed |
| pubmed-article:8864439 | pubmed:affiliation | Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Medical Center, Philadelphia, USA. | lld:pubmed |
| pubmed-article:8864439 | pubmed:publicationType | Journal Article | lld:pubmed |
